This clinical trial is focused on studying the effects of an anti-inflammatory treatment for patients who have experienced an aneurysmal subarachnoid hemorrhage (SAH). This condition occurs when there is bleeding in the space surrounding the brain, often due to a burst blood vessel. The treatment being tested is called dexamethasone sodium phosphate, which is a medication used to reduce inflammation. In this study, some patients will receive dexamethasone, while others will receive a placebo, which looks like the medication but does not contain the active substance.

The purpose of the study is to understand how dexamethasone affects recovery in patients with SAH, whether or not they initially show signs of inflammation in their blood. Participants in the study will receive either the dexamethasone treatment or a placebo. The study will monitor patients over a period of time to assess their recovery and any changes in their condition. This includes looking at survival rates, the length of time spent in the hospital, and any complications that may arise, such as delayed ischemic neurological deficits, which are problems with brain function that occur after the initial bleeding.

Throughout the study, various health indicators will be measured, such as levels of inflammation in the blood and overall quality of life. The study aims to provide valuable insights into whether dexamethasone can improve outcomes for patients who have suffered from an aneurysmal subarachnoid hemorrhage. The results will help determine if this treatment can be beneficial in managing the condition and improving patient recovery.